Literature DB >> 24396870

Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1.

Yonghua Han, Yuchen Liu, Hu Zhang, Tiantian Wang, Ruiying Diao, Zhimao Jiang, Yaoting Gui, Zhiming Cai.   

Abstract

MicroRNAs mainly inhibit coding genes and long non-coding RNA expression. Here, we report that hsa-miR-125b and oncogene SIRT7/oncogenic long non-coding RNA MALAT1 were inversely expressed in bladder cancer. Hsa-miR-125b mimic down-regulated, whereas hsa-miR-125b inhibitor up-regulated the expression of SIRT7 and MALAT1. Binding sites were confirmed between hsa-miR-125b and SIRT7/MALAT1. Up-regulation of hsa-miR-125b or down-regulation of SIRT7 inhibited proliferation, motility and increased apoptosis. The effects of up-regulation of hsa-miR-125b were similar to that of silencing MALAT1 in bladder cancer as we had previously described. These data suggest that hsa-miR-125b suppresses bladder cancer development via inhibiting SIRT7 and MALAT1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24396870

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  72 in total

1.  MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer.

Authors:  Tian Yang; Asmitananda Thakur; Tianjun Chen; Li Yang; Gao Lei; Yiqian Liang; Shuo Zhang; Hui Ren; Mingwei Chen
Journal:  Tumour Biol       Date:  2015-01-22

Review 2.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

3.  Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813.

Authors:  Peng Hu; Jianying Shangguan; Leida Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 4.  Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer.

Authors:  Mohammadreza Hajjari; Atefeh Khoshnevisan; Young Kee Shin
Journal:  Tumour Biol       Date:  2014-09-30

5.  Prioritization of non-coding disease-causing variants and long non-coding RNAs in liver cancer.

Authors:  Hua Li; Zekun He; Yang Gu; Lin Fang; Xin Lv
Journal:  Oncol Lett       Date:  2016-09-14       Impact factor: 2.967

6.  [Role of long noncoding RNA MALAT1 promotes the occurrence and progression of cutaneous squamous cell carcinoma].

Authors:  Shan-Shan Li; Liang Zhou; Lin Gao; Ying-Hui Wang; Zhen-Hua Ding
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

7.  MicroRNA-125b targeted STAT3 to inhibit laryngeal squamous cell carcinoma cell growth and motility.

Authors:  Juan Feng; Yuqin Fan; Qukuerhan Ayiheng; Hua Zhang; Jun Yong; Bin Hu
Journal:  Oncol Lett       Date:  2017-05-11       Impact factor: 2.967

Review 8.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

9.  MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma.

Authors:  Jie Zhang; Sijia Na; Caiyue Liu; Shuting Pan; Junying Cai; Jiaxuan Qiu
Journal:  Tumour Biol       Date:  2015-11-23

10.  Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications.

Authors:  Danyang Ren; Huiying Li; Renqiu Li; Jianming Sun; Pin Guo; Huiyun Han; Yuehuang Yang; Jun Li
Journal:  Oncol Lett       Date:  2016-01-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.